Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(85 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
current items will be put into the subsections.
 
subsections with contents are marked ''with content''.
 
the others are pending data.
 
  
*[[reviews on covid drug development]] ''with content''
+
*'''[[scouting ideas]]'''
*
+
  
*[[Patients on biologicals]]
+
*'''[[PHA Biologicals]]'''
*[[HMGB1, RAGE]]
+
*[[pre-Interleukin 6]] ''with content''
+
*[[post-Interleukin 6]]
+
*[[pre-TNFalpha]]
+
*[[post-TNFalpha]]
+
*[[pre-Interleukin 17]]
+
*[[post-Interleukin 17]]
+
*[[pre-Interleukin 1]]
+
*[[post-Interleukin 1]]
+
*[[Inflammasome]]
+
  
*[[NK-kappaB]]
+
*'''[[PHA conventional pharmacology]]'''
*[[STAT 3]]
+
*[[JAK Janus Kinase]]
+
*[[Cytokine absorbers]]
+
*[[Target Complement system]]
+
*[[Target Extracellular traps]]
+
*[[Anticoagulant in covid19]]
+
*[[Antioxidants]]
+
*[[Stem cells]]
+
*[[MDSC cells]]
+
  
 +
*'''[[PHA retargeted compounds]]'''
  
 +
*'''[[PHA antivirals by mechanism]]'''
  
*
+
*'''[[PHA pharmacophore by screened target]]'''
*[[Hydroxychloroquine]] ''with content''
+
*
+
  
*[[AV Remdesivir]]
+
*'''[[PHA ImmunoNutrients]]
*[[AV Lopinavir]]
+
*[[AV Ivermectin]]
+
*[[Interferons]]
+
*[[Vitamin D]]
+
  
*[[Statins]]
+
*'''[[PHA compl altern natural]]'''
*[[Anorganic nutrients Magnesium]]
+
*[[Anorganic nutrients Selenium]]
+
*[[Anorganic nutrients Zinc]]
+
  
 +
*'''[[PHA within indications compounds]]'''
  
 +
*'''[[PHA Serum products]]'''
  
*[[Traditional Chinese Medicine]]
+
*'''[[PHA Vaccination]]'''
*[[Natural compounds]]
+
*[[Retargeted single compounds]]
+
  
*[[Target ACE2, Spike protein]]
+
PHA related options:
*[[Target TMPRSS2, Spike protein]]
+
*[[Reconvalescent blood products, Passive vaccine]]
+
*[[Plasmapheresis]]
+
  
 +
*[[Radiation therapy]]
 +
*[[Phototherapy]]
 +
*[[Electric fields]]
 +
*[[Treatment other concepts]]
  
*[[Active vaccine]]
 
  
 +
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
{{tp|p=32162456|t=2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep  Docking of 1 3 Billion Compounds |pdf=|usr=}}
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
 +
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
 +
based on e.g.
  
 +
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
  
'''Icatibant''' bradykinin antagonist
+
=======================================================================================
{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
+
  
'''Arbidol''' retarget influenza
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32373347|t=2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro |pdf=|usr=}}
+
  
'''Macrolide antibiotics'''
+
  =======================================================================================
{{tp|p=32249257|t=2020. Macrolide treatment for COVID-19: Will this be the way forward?|pdf=|usr=}}
+
 
+
'''Oleoylethanolamide'''
+
{{tp|p=32327293|t=ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |pdf=|usr=}}
+
 
+
'''Metronidazole''' retarget
+
{{tp|p=32259129|t=2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen |pdf=|usr=}}
+
 
+
'''Glutathione GSH''' antioxidant
+
*[https://nypost.com/2020/05/09/new-york-mom-with-coronavirus-saved-by-medical-student-son/ found in a forrest gump mode]
+
*[https://www.sciencedirect.com/science/article/pii/S2213007120301350 Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases]
+
 
+
'''Chlorpromazine''' retarget
+
*[https://www.biorxiv.org/content/10.1101/2020.05.05.079608v1 paper]
+
 
+
'''Zinc''' add-on
+
*[https://www.sciencedirect.com/science/article/pii/S0306987720306435 call for trial]
+
 
+
'''Selenium'''
+
{{tp|p=32342979|t=ä. Association between regional selenium status and reported outcome of COVID-19 cases in China |pdf=|usr=}}
+
 
+
'''Remdesivir''' retarget
+
*[https://gab.com/Remnant601/posts/104122987152232660 one hospital on...]
+
{{tp|p=32283108|t=ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites |pdf=|usr=}}
+
{{tp|p=32020029|t=2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |pdf=|usr=}}
+
 
+
'''Lauric acid''' nat. compd.
+
*[https://www.icp.org.ph/2020/01/the-potential-of-coconut-oil-and-its-derivatives-as-effective-and-safe-antiviral-agents-against-the-novel-coronavirus-ncov-2019/ call for trial]
+
 
+
'''Nicotine''' nat. toxin
+
*[https://www.usatoday.com/story/news/factcheck/2020/05/03/covid-19-fact-check-caution-urged-study-virus-smoking/3055378001/ france]
+
 
+
'''Niclosamide'''
+
{{tp|p=32125140|t=ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |pdf=|usr=}}
+
 
+
'''Microbiome as target'''
+
{{tp|p=32356654|t=ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles |pdf=|usr=}}
+
 
+
'''ACE2 as target'''
+
{{tp|p=32286790|t=ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32333836|t=ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 |pdf=|usr=}}
+
 
+
 
+
'''Garlic extracts'''
+
{{tp|p=32363255|t=ä. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil |pdf=|usr=}}
+
 
+
'''Dipyridamole''' retarget
+
{{tp|p=32318327|t=ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 |pdf=|usr=}}
+
 
+
'''stem cells'''
+
{{tp|p=32257554|t=2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia |pdf=|usr=}}
+
{{tp|p=32257537|t=2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia |pdf=|usr=}}
+
{{tp|p=32283815|t=2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use |pdf=|usr=}}
+
 
+
 
+
'''Ivermectin'''
+
{{tp|p=32330482|t=ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an  FDA warning, two letters to the editor and the authors  responses |pdf=|usr=}}
+
 
+
'''Various Leads'''
+
*[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone]
+
*[https://doi.org/10.1038/s41586-020-2286-9 paper in nature]
+
{{tp|p=32251767|t=2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |pdf=|usr=}}
+
 
+
 
+
'''Interferons'''
+
{{tp|p=32275914|t=2020. Type 1 interferons as a potential treatment against COVID-19 |pdf=|usr=}}
+
{{tp|p=32360182|t=2020. Antiviral activities of type I interferons to SARS-CoV-2 infection |pdf=|usr=}}
+
 
+
'''Plasmapheresis'''
+
 
+
'''Reconvalescent sera'''
+
{{tp|p=32243945|t=ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection |pdf=|usr=}}
+
 
+
'''Therapeutic antibodies (virus-targeted)'''
+
*[https://www.foxnews.com/science/man-made-antibody-neutralizes-coronavirus-first-time anti covid mab]
+
*[https://www.telegraaf.nl/nieuws/750205601/nederlands-antilichaam-47-d11-blokkeert-infectie-coronavirus acmab 47d11]
+
{{tp|p=32375025|t=ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain  Camelid Antibodies |pdf=|usr=}}
+
 
+
 
+
 
+
{{tp|p=32241793|t=2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies |pdf=|usr=}}
+
 
+
 
+
 
+
'''Glucocorticoids'''
+
 
+
{{tp|p=32149773|t=ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial |pdf=|usr=}}
+
 
+
'''CRISPR genome editing technology'''
+
{{tp|p=32353252|t=ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |pdf=|usr=}}
+
 
+
'''Virus interference'''
+
{{tp|p=32071427|t=2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses |pdf=|usr=}}
+
 
+
'''Other antirheumatic compounds'''
+
 
+
 
+
 
+
 
+
 
+
'''Chemoprevention Covid19'''
+
 
+
'''Antiviral agents Covid19'''
+
{{tp|p=32231345|t=2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high  capacity to mediate membrane fusion |pdf=|usr=}}
+
 
+
'''Lung regeneration and repair after Covid19'''
+
 
+
'''resilience enhancement'''
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32311498|t=ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
 
+
'''psychoneuroimmunology'''
+
{{tp|p=32234338|t=ä. Using psychoneuroimmunity against COVID-19 |pdf=|usr=}}
+
 
+
'''cannabinoids'''
+
{{tp|p=32360437|t=ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?|pdf=|usr=}}
+
 
+
 
+
'''Complementary & Traditional chinese medicine & Ethnopharm'''
+
{{tp|p=32245701|t=ä. Is traditional Chinese medicine useful in the treatment of COVID-19?|pdf=|usr=}}
+
{{tp|p=32233641|t=2020. Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19 |pdf=|usr=}}
+
*[https://www.aa.com.tr/en/africa/madagascar-slams-who-for-not-endorsing-its-herbal-cure/1836905 madagascar herbs]
+
{{tp|p=32229706|t=2020. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?|pdf=|usr=}}
+
{{tp|p=32037389|t=2020. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment |pdf=|usr=}}
+
{{tp|p=32334064|t=ä. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet |pdf=|usr=}}
+
{{tp|p=32361935|t=ä. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32065348|t=ä. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs |pdf=|usr=}}
+
{{tp|p=32308732|t=2020. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China |pdf=|usr=}}
+
 
+
'''Exercise'''
+
{{tp|p=32311497|t=ä. The immunological case for staying active during the COVID-19 pandemic |pdf=|usr=}}
+
 
+
'''Topical agents''' opening up the world of nano...
+
*[https://www.dailymail.co.uk/sciencetech/article-8315269/Commercial-mouthwash-prevent-COVID-19-transmission-scientists-say.html on mouth rinses]
+
 
+
 
+
 
+
 
+
'''Vaccination Covid19'''
+
{{tp|p=32105090|t=2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic |pdf=|usr=}}
+
*[https://patch.com/massachusetts/cambridge/ma-company-takes-critical-step-toward-covid-19-vaccine mrna-1273, moderna]
+
 
+
{{tp|p=32183941|t=2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for  Immune Responses to SARS-CoV-2 |pdf=|usr=}}
+
----
+
 
+
 
+
 
+
{{tp|p=32272008|t=2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2 |pdf=|usr=}}
+
 
+
{{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}}
+
{{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}}
+
{{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}}
+
{{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
+
 
+
{{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32266375|t=ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality |pdf=|usr=}}
+
 
+
{{tp|p=32301957|t=ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32344167|t=ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study |pdf=|usr=}}
+
{{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
+
 
+
{{tp|p=32277367|t=ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |pdf=|usr=}}
+
{{tp|p=32373721|t=2020. Low dose lung radiotherapy for COVID-19 pneumonia  The rationale for a cost-effective anti-inflammatory treatment |pdf=|usr=}}
+
 
+
{{tp|p=32209231|t=2020. Computers and viral diseases  Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus |pdf=|usr=}}
+
{{tp|p=32264963|t=2020. A new clinical trial to test high-dose vitamin C in patients with COVID-19 |pdf=|usr=}}
+
 
+
 
+
 
+
{{tp|p=32241301|t=2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |pdf=|usr=}}
+
{{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
+
{{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}}
+
 
+
{{tp|p=32219057|t=ä. The SARS-CoV-2 Vaccine Pipeline: an Overview |pdf=|usr=}}
+
{{tp|p=32360420|t=ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia |pdf=|usr=}}
+
 
+
 
+
 
+
{{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}}
+
{{tp|p=32333972|t=ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4  inhibition play a role?? |pdf=|usr=}}
+
{{tp|p=32333966|t=2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |pdf=|usr=}}
+
{{tp|p=32333969|t=ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too |pdf=|usr=}}
+
{{tp|p=32283128|t=ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?|pdf=|usr=}} ''on ace2 via adam17, nfkb via dpp4''
+
 
+
 
+
 
+
{{tp|p=32378648|t=2020. Rapid review for the anti-coronavirus effect of remdesivir |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
 
+
{{tp|p=32344202|t=2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy  and vaccine development |pdf=|usr=}}
+
{{tp|p=32249203|t=ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and  rapid translational development |pdf=|usr=}}
+
 
+
{{tp|p=32379923|t=2020. Is BCG vaccination causally related to reduced COVID-19 mortality?|pdf=|usr=}}
+
{{tp|p=32333818|t=2020. COVID-19: lambda interferon against viral load and hyperinflammation |pdf=|usr=}}
+
 
+
{{tp|p=32228222|t=2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension |pdf=|usr=}}
+
{{tp|p=32148172|t=2020. Timely development of vaccines against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=C7118608|t=ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System |pdf=|usr=}}
+
{{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}}
+
{{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pdf=|usr=}}
+
{{tp|p=32292627|t=ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32347925|t=ä. Statin therapy in COVID-19 infection |pdf=|usr=}}
+
 
+
{{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
+
{{tp|p=32282032|t=ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |pdf=|usr=}}
+
{{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
+
{{tp|p=C7129866|t=ä. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19 |pdf=|usr=}}
+
{{tp|p=32341100|t=2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective |pdf=|usr=}}
+
{{tp|p=32265310|t=ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19 |pdf=|usr=}}
+
{{tp|p=32271462|t=2020. Inositol and pulmonary function  Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}}
+
{{tp|p=32271456|t=2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease  2019 |pdf=|usr=}}
+
{{tp|p=32271454|t=2020. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19 |pdf=|usr=}}
+
{{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}}
+
{{tp|p=32329879|t=2020. (Naturlal products: )An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections |pdf=|usr=}}
+
{{tp|p=32327396|t=ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?|pdf=|usr=}}
+
{{tp|p=32279655|t=2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?|pdf=|usr=}}
+
 
+
{{tp|p=32329380|t=2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia |pdf=|usr=}}
+
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}}
+
 
+
{{tp|p=32269766|t=2020. In silico identification of vaccine targets for 2019-nCoV |pdf=|usr=}}
+
 
+
{{tp|p=32374074|t=2020. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease |pdf=|usr=}}
+
{{tp|p=32265848|t=2020. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses |pdf=|usr=}}
+
{{tp|p=32251729|t=ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design |pdf=|usr=}}
+
{{tp|p=32363144|t=ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin |pdf=|usr=}}
+
 
+
{{tp|p=32247692|t=ä. Faecal-oral transmission of SARS-COV-2: practical implications |pdf=|usr=}}
+
{{tp|p=32367287|t=ä. New evidence of SARS-CoV-2 transmission through the ocular surface |pdf=|usr=}}
+
 
+
{{tp|p=32313872|t=ä. COVID-19 convalescent plasma transfusion |pdf=|usr=}}
+
{{tp|p=32251365|t=ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy |pdf=|usr=}}
+
{{tp|p=32375153|t=2020. HMGB1: A Possible Crucial Therapeutic Target for COVID-19?|pdf=|usr=}}
+
{{tp|p=32186952|t=2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing  and developing vaccines, immunotherapeutics, and therapeutics |pdf=|usr=}}
+
 
+
{{tp|p=32300370|t=2020. Can an effective SARS-CoV-2 vaccine be developed for the older population?|pdf=|usr=}}
+
{{tp|p=32259480|t=ä. SARS-CoV-2 Vaccines: Status Report |pdf=|usr=}}
+
{{tp|p=32362644|t=2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32366728|t=2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience |pdf=|usr=}}
+
{{tp|p=32366726|t=2020. Management of Asthma in Children during COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32366725|t=2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology |pdf=|usr=}}
+
 
+
{{tp|p=32358227|t=2020. Demystifying BCG Vaccine and COVID-19 Relationship |pdf=|usr=}}
+
{{tp|p=32291382|t=2020. Coronavirus Vaccines: Light at the End of the Tunnel |pdf=|usr=}}
+
{{tp|p=32238614|t=2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak |pdf=|usr=}}
+
{{tp|p=32321620|t=ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword |pdf=|usr=}}
+
{{tp|p=32341599|t=2020. Is Immuno-modulation the Key to COVID-19 Pandemic?|pdf=|usr=}}
+
 
+
 
+
{{tp|p=32328406|t=ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32342098|t=ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib |pdf=|usr=}}
+
{{tp|p=32372149|t=ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?|pdf=|usr=}}
+
{{tp|p=32352026|t=2020. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach |pdf=|usr=}}
+
{{tp|p=32272396|t=ä. The Possible of Immunotherapy for COVID-19: a Systematic Review |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32234466|t=ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32259575|t=ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF  COVID 19 |pdf=|usr=}}
+
{{tp|p=32361028|t=ä. ?Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ? |pdf=|usr=}}
+
 
+
{{tp|p=32251731|t=ä. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection |pdf=|usr=}}
+
{{tp|p=32360231|t=ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?|pdf=|usr=}}
+
{{tp|p=32335281|t=ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32298745|t=ä. Successful treatment of plasma exchange followed by intravenous immunogloblin in  a critically ill patient with 2019 novel coronavirus infection |pdf=|usr=}}
+
 
+
{{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in  SARS-CoV-2 Infections |pdf=|usr=}}
+
 
+
{{tp|p=32179150|t=ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?|pdf=|usr=}}
+
{{tp|p=32147516|t=ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections |pdf=|usr=}}
+
 
+
{{tp|p=32226290|t=2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |pdf=|usr=}}
+
{{tp|p=32226288|t=2020. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New  Coronavirus (SARS-CoV-2): A Review and Perspective |pdf=|usr=}}
+
{{tp|p=32226289|t=2020. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32300868|t=ä. Balneotherapy and human immune function in the era of COVID-19 |pdf=|usr=}}
+
{{tp|p=32321655|t=ä. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients |pdf=|usr=}}
+
{{tp|p=32251768|t=2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |pdf=|usr=}}
+
 
+
*[https://www.infowars.com/experts-suggest-90-million-oxford-university-coronavirus-vaccine-doesnt-work/ Oxford vaccine failed in monkeys]
+
{{tp|p=32305009|t=ä. Investigating hypothiocyanite against SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32173576|t=2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression |pdf=|usr=}}
+
{{tp|p=32218340|t=2020. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?|pdf=|usr=}}
+
{{tp|p=32354030|t=2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work |pdf=|usr=}}
+
 
+
{{tp|p=32353978|t=2020. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design |pdf=|usr=}}
+
 
+
{{tp|p=32368489|t=2020. The pathogenesis and alternative treatment of SARS-CoV2 |pdf=|usr=}}
+
{{tp|p=32289016|t=2020. Herbal medicine and pattern identification for treating COVID-19: a rapid review  of guidelines |pdf=|usr=}}
+
{{tp|p=32125455|t=ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |pdf=|usr=}}
+
{{tp|p=32347443|t=ä. Camostat mesilate therapy for COVID-19 |pdf=|usr=}}
+
{{tp|p=32333086|t=ä. Remdesivir bei Patienten mit schwerer COVID-19 |pdf=|usr=}}
+
{{tp|p=32378817|t=2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients |pdf=|usr=}}
+
*[https://www.nature.com/articles/d41573-020-00073-5 Nature: The COVID-19 vaccine development landscape]
+
{{tp|p=32283237|t=ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?|pdf=|usr=}}
+
{{tp|p=32278797|t=ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2 |pdf=|usr=}}
+
{{tp|p=32339701|t=ä. Potential role of Janus kinase inhibitors in COVID-19 |pdf=|usr=}}
+
{{tp|p=32344070|t=ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32283123|t=ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus  Disease 2019) Treatment |pdf=|usr=}}
+
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
+
{{tp|p=32361744|t=ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease |pdf=|usr=}}
+
{{tp|p=32196083|t=ä. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression |pdf=|usr=}}
+
{{tp|p=32317220|t=ä. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32284326|t=2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency |pdf=|usr=}}
+
{{tp|p=32094225|t=2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase  from Middle East respiratory syndrome coronavirus |pdf=|usr=}}
+
{{tp|p=32295479|t=2020. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study |pdf=|usr=}}
+
{{tp|p=32306862|t=2020. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes |pdf=|usr=}}
+
{{tp|p=32266873|t=2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase |pdf=|usr=}}
+
{{tp|p=32238078|t=2020. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel |pdf=|usr=}}
+
 
+
{{tp|p=32374474|t=2020. Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
{{tp|p=32254064|t=2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19 |pdf=|usr=}}
+
{{tp|p=32352407|t=2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor  antagonists |pdf=|usr=}}
+
{{tp|p=32167489|t=ä. The convalescent sera option for containing COVID-19 |pdf=|usr=}}
+
{{tp|p=32326602|t=2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |pdf=|usr=}}
+
{{tp|p=32326426|t=2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32305026|t=ä. Challenges of Convalescent Plasma Therapy on COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32289152|t=2020. COVID-19 and emerging viral infections: The case for interferon lambda |pdf=|usr=}}
+
{{tp|p=32302401|t=2020. Targeting potential drivers of COVID-19: Neutrophil extracellular traps |pdf=|usr=}}
+
{{tp|p=32359878|t=2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19 |pdf=|usr=}}
+
 
+
{{tp|p=32171450|t=2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus |pdf=|usr=}}
+
{{tp|p=32173287|t=ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines |pdf=|usr=}}
+
{{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans''
+
{{tp|p=32372051|t=ä. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2 |pdf=|usr=}}
+
{{tp|p=32335161|t=ä. In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers |pdf=|usr=}}
+
 
+
{{tp|p=32171872|t=ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study |pdf=|usr=}}
+
{{tp|p=32333918|t=ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact |pdf=|usr=}}
+
{{tp|p=32283153|t=ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1 |pdf=|usr=}}
+
{{tp|p=32362440|t=ä. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases |pdf=|usr=}}
+
{{tp|p=32232474|t=ä. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure |pdf=|usr=}}
+
{{tp|p=32348485|t=ä. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19  Patients |pdf=|usr=}}
+
{{tp|p=32348489|t=ä. COVID-19: Is Everything Appropriate to Create an Effective Vaccine?|pdf=|usr=}}
+
 
+
{{tp|p=32293807|t=2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment |pdf=|usr=}}
+
{{tp|p=32307268|t=2020. Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC?MSE analysis |pdf=|usr=}}
+
{{tp|p=32122812|t=2020. Traditional Chinese medicine is a resource for drug discovery against 2019 novel  coronavirus (SARS-CoV-2) |pdf=|usr=}}
+
{{tp|p=32113846|t=ä. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus |pdf=|usr=}}
+
{{tp|p=32080993|t=2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for  the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32080992|t=2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission  of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for  the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32056407|t=2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR |pdf=|usr=}}
+
{{tp|p=32281317|t=2020. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea |pdf=|usr=}}
+
{{tp|p=32356252|t=ä. COVID-19: Therapeutics and Their Toxicities |pdf=|usr=}}
+
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
+
{{tp|p=32052466|t=2020. Potential interventions for novel coronavirus in China: A systematic review |pdf=|usr=}}
+
{{tp|p=32022276|t=2020. Immunoinformatics?aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019?nCoV |pdf=|usr=}}
+
{{ttp|p=32249185|t=ä. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection |pdf=|usr=}}
+
{{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}}
+
*[https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds on ivermectin]
+
 
+
 
+
{{tp|p=32331982|t=ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan |pdf=|usr=}}
+
{{tp|p=32236561|t=ä. Combating COVID-19 with Chloroquine |pdf=|usr=}}
+
 
+
{{tp|p=32296570|t=ä. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants? |pdf=|usr=}}
+
{{tp|p=32346490|t=ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase |pdf=|usr=}}
+
{{tp|p=32324533|t=2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients |pdf=|usr=}}
+
 
+
{{tp|p=32291198|t=2020. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management |pdf=|usr=}}
+
 
+
{{tp|p=32353597|t=ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy |pdf=|usr=}}
+
{{tp|p=32281481|t=2020. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review |pdf=|usr=}}
+
{{tp|p=32370758|t=2020. SARS-CoV-2 RNA polymerase as target for antiviral therapy |pdf=|usr=}}
+
 
+
{{tp|p=32313848|t=ä. Precision medicine in COVID-19: IL-1 beta a potential target |pdf=|usr=}}
+
{{tp|p=32219428|t=2020. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma |pdf=|usr=}}
+
 
+
 
+
{{tp|p=32321635|t=2020. Old and new antirheumatic drugs for the treatment of COVID-19 |pdf=|usr=}}
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis